Necrostatin-1

CAS No. 4311-88-0

Necrostatin-1( Nec-1 )

Catalog No. M14462 CAS No. 4311-88-0

Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 27 In Stock
10MG 42 In Stock
25MG 77 In Stock
50MG 132 In Stock
100MG 164 In Stock
200MG 246 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Necrostatin-1
  • Note
    Research use only, not for human use.
  • Brief Description
    Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.
  • Description
    Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Nec-1
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    RIP1
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    4311-88-0
  • Formula Weight
    259.33
  • Molecular Formula
    C13H13N3OS
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 51 mg/mL warmed (196.66 mM)
  • SMILES
    O=C(C(CC1=CNC2=C1C=CC=C2)N3)N(C)C3=S
  • Chemical Name
    5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Han W, et al. Apoptosis. 2009 May;14(5):674-86.
molnova catalog
related products
  • MOSLOFLAVONE

    MOSLOFLAVONE showed promising anti-inflammatory activity via inhibition of TNF-α and IL-1β with IC50 values of 0.71 μM and ?7.8 μM respectively.

  • TNF-α-IN-9

    TNF-α-IN-9 is an NDM-1 inhibitor-3 analog and is a TNF-α inhibitor.TNF-α-IN-9 shows low inhibitory activity.

  • Certolizumab pegol

    Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).